| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Corinne Brühlmann, Andrew Marston, Kurt Hostettmann, Pierre-Alain Carrupt, Bernard Test. Screening of non-alkaloidal natural compounds as acetylcholinesterase inhibitors. Chemistry & biodiversity. vol 1. issue 6. 2007-02-19. PMID:17191882. |
acetylcholinesterase (ache) inhibitors are currently the only approved therapy for the treatment of alzheimer's disease, only a limited number of drugs are commercially available. |
2007-02-19 |
2023-08-12 |
Not clear |
| Rafael Blesa, Roger Bullock, Yunsheng He, Howard Bergman, Giuseppe Gambina, Joanne Meyer, Günter Rapatz, Jennifer Nagel, Roger Lan. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenetics and genomics. vol 16. issue 11. 2007-02-06. PMID:17047484. |
a randomized double-blind trial evaluated the efficacy and tolerability of rivastigmine, an inhibitor of acetylcholinesterase (ache) and butyrylcholinesterase (buche), and donepezil, an ache-selective inhibitor, in patients with alzheimer's disease over a 2-year period. |
2007-02-06 |
2023-08-12 |
Not clear |
| Hai Yan Zhang, Xi Can Tan. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends in pharmacological sciences. vol 27. issue 12. 2007-01-11. PMID:17056129. |
in recent years, the most common pharmacological treatment for alzheimer's disease (ad) has been acetylcholinesterase (ache) inhibition. |
2007-01-11 |
2023-08-12 |
Not clear |
| Carlos H T P da Silva, Vanessa Leiria Campo, Ivone Carvalho, Carlton A Taf. Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease. Journal of molecular graphics & modelling. vol 25. issue 2. 2007-01-08. PMID:16413803. |
molecular modeling techniques were of utmost importance to design a new pharmaceutical against alzheimer's disease, with potential inhibitory activity over ache, since the inhibition of human plasma butyrylcholinesterase (bche) may cause side effects. |
2007-01-08 |
2023-08-12 |
human |
| Yvonne Schott, Michael Decker, Hans Rommelspacher, Jochen Lehman. 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorganic & medicinal chemistry letters. vol 16. issue 22. 2007-01-03. PMID:16945529. |
in the course of studies directed toward the discovery of novel acetyl- and butyrylcholinesterase (ache and bche) inhibitors for the treatment of alzheimer's disease, we focused on beta-carbolines (bcs). |
2007-01-03 |
2023-08-12 |
Not clear |
| Yuki Takator. [Mechanisms of neuroprotective effects of therapeutic acetylcholinesterase inhibitors used in treatment of Alzheimer's disease]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. vol 126. issue 8. 2006-11-03. PMID:16880719. |
donepezil, galanthamine, and tacrine are therapeutic acetylcholinesterase (ache) inhibitors used for the treatment of alzheimer's disease. |
2006-11-03 |
2023-08-12 |
rat |
| L Gandía, R M Alvarez, J M Hernández-Guijo, J M González-Rubio, R de Pascual, J Rojo, L Tapi. [Anticholinesterases in the treatment of Alzheimer's disease]. Revista de neurologia. vol 42. issue 8. 2006-10-18. PMID:16625509. |
this led to the formulation of the so-called cholinergic theory of alzheimer, which provides the rationale behind the use of the drugs that are currently available to treat this disease, namely, acetylcholine esterase (ache) inhibitors (rivastigmine, donepezil and galanthamine). |
2006-10-18 |
2023-08-12 |
Not clear |
| Hongjun Fu, Wenming Li, Yuanzhi Lao, Jialie Luo, Nelson T K Lee, Kelvin K W Kan, Hing Wai Tsang, Karl W K Tsim, Yuanping Pang, Zhiwang Li, Donald C Chang, Mingtao Li, Yifan Ha. Bis(7)-tacrine attenuates beta amyloid-induced neuronal apoptosis by regulating L-type calcium channels. Journal of neurochemistry. vol 98. issue 5. 2006-10-03. PMID:16771827. |
beta amyloid protein (abeta) and acetylcholinesterase (ache) have been shown to be closely implicated in the pathogenesis of alzheimer's disease. |
2006-10-03 |
2023-08-12 |
Not clear |
| Kornkanok Ingkaninan, Preeda Phengpa, Supreeya Yuenyongsawad, Nantaka Khoran. Acetylcholinesterase inhibitors from Stephania venosa tuber. The Journal of pharmacy and pharmacology. vol 58. issue 5. 2006-09-29. PMID:16640839. |
acetylcholinesterase (ache) inhibitors have lately gained interest as potential drugs in the treatment of alzheimer's disease. |
2006-09-29 |
2023-08-12 |
Not clear |
| Edson X Albuquerque, Edna F R Pereira, Yasco Aracava, William P Fawcett, Maristela Oliveira, William R Randall, Tracey A Hamilton, Robert K Kan, James A Romano, Michael Adle. Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents. Proceedings of the National Academy of Sciences of the United States of America. vol 103. issue 35. 2006-09-29. PMID:16914529. |
here, we demonstrate that galantamine, a reversible and centrally acting ache inhibitor approved for treatment of mild to moderate alzheimer's disease, protects guinea pigs from the acute toxicity of lethal doses of the nerve agents soman and sarin, and of paraoxon, the active metabolite of the insecticide parathion. |
2006-09-29 |
2023-08-12 |
Not clear |
| Agneta Nordber. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer disease and associated disorders. vol 20. issue 2 Suppl 1. 2006-09-28. PMID:16772751. |
inhibitors of the enzyme acetylcholinesterase (ache) are presently used as long-term symptomatic treatments for patients with alzheimer disease (ad), as they enhance central levels of synaptic acetylcholine. |
2006-09-28 |
2023-08-12 |
Not clear |
| Roger M Lane, Steven G Potkin, Albert En. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. The international journal of neuropsychopharmacology. vol 9. issue 1. 2006-09-19. PMID:16083515. |
inhibition of brain acetylcholinesterase (ache) has been the major therapeutic target of che-i treatment strategies for alzheimer's disease (ad). |
2006-09-19 |
2023-08-12 |
Not clear |
| M Pera, S Román, M Ratia, P Camps, D Muñoz-Torrero, L Colombo, C Manzoni, M Salmona, A Badia, M V Clo. Acetylcholinesterase triggers the aggregation of PrP 106-126. Biochemical and biophysical research communications. vol 346. issue 1. 2006-08-28. PMID:16750169. |
the presence of prion protein (prp) in alzheimer's disease (ad) senile plaques prompted us to assess if ache could trigger the prp peptides aggregation as well. |
2006-08-28 |
2023-08-12 |
Not clear |
| Sophia Diamant, Erez Podoly, Assaf Friedler, Hagai Ligumsky, Oded Livnah, Hermona Sore. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proceedings of the National Academy of Sciences of the United States of America. vol 103. issue 23. 2006-07-19. PMID:16731619. |
in alzheimer's disease, both acetylcholinesterase (ache) and butyrylcholinesterase (bche) colocalize with brain fibrils of amyloid-beta (abeta) peptides, and synaptic ache-s facilitates fibril formation by association with insoluble abeta fibrils. |
2006-07-19 |
2023-08-12 |
human |
| Sophia Diamant, Erez Podoly, Assaf Friedler, Hagai Ligumsky, Oded Livnah, Hermona Sore. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proceedings of the National Academy of Sciences of the United States of America. vol 103. issue 23. 2006-07-19. PMID:16731619. |
in alzheimer's disease, bche may have thus acquired an inverse role to that of ache by adopting imperfect amphipathic characteristics of its c terminus. |
2006-07-19 |
2023-08-12 |
human |
| N I Bohnen, D I Kaufer, R Hendrickson, L S Ivanco, B J Lopresti, G M Constantine, Ch A Mathis, J G Davis, R Y Moore, S T Dekosk. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. Journal of neurology. vol 253. issue 2. 2006-06-28. PMID:16133720. |
we recently reported findings that loss of cortical acetylcholinesterase (ache) activity is greater in parkinsonian dementia than in alzheimer's disease (ad). |
2006-06-28 |
2023-08-12 |
human |
| Sang-Yoon Lee, Yearn Seong Choe, Eun Kyoung Ryu, Yoichi Iimura, Yong Choi, Kyung-Han Lee, Byung-Tae Ki. Is subnanomolar binding affinity required for the in vivo imaging of acetylcholinesterase? Studies on 18F-labeled G379. Nuclear medicine and biology. vol 33. issue 1. 2006-06-19. PMID:16459263. |
acetylcholinesterase (ache) is an important cholinergic marker of alzheimer's disease (ad) and shows reduced activity in postmortem ad brain tissues. |
2006-06-19 |
2023-08-12 |
mouse |
| Maria Laura Bolognesi, Vincenza Andrisano, Manuela Bartolini, Andrea Cavalli, Anna Minarini, Maurizio Recanatini, Michela Rosini, Vincenzo Tumiatti, Carlo Melchiorr. Heterocyclic inhibitors of AChE acylation and peripheral sites. Farmaco (Societa chimica italiana : 1989). vol 60. issue 6-7. 2006-06-06. PMID:15878569. |
notwithstanding the criticism to the so called " cholinergic hypothesis", the therapeutic strategies for the treatment of alzheimer's disease (ad) have been mainly centered on the restoration of cholinergic functionality and, until the last year, the only drugs licensed for the management of ad were the acetycholinesterase (ache) inhibitors. |
2006-06-06 |
2023-08-12 |
Not clear |
| M Villarroya, A G García, J L Marc. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease. Current pharmaceutical design. vol 10. issue 25. 2006-04-10. PMID:15544507. |
new classes of ache inhibitors with additional pharmacological effects of interest for the treatment of alzheimer's disease. |
2006-04-10 |
2023-08-12 |
Not clear |
| David E Kuhl, Robert A Koeppe, Scott E Snyder, Satoshi Minoshima, Kirk A Frey, Michael R Kilbour. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Annals of neurology. vol 59. issue 1. 2006-03-23. PMID:16278840. |
we tested the premise that cholinesterase inhibitor therapy should target butyrylcholinesterase (buche) in alzheimer's disease (ad), not acetylcholinesterase (ache) alone, because both enzymes hydrolyze acetylcholine, and buche is increased in ad cerebral cortex. |
2006-03-23 |
2023-08-12 |
Not clear |